Format

Send to

Choose Destination
See comment in PubMed Commons below
Semin Nephrol. 2013 Sep;33(5):448-56. doi: 10.1016/j.semnephrol.2013.07.006.

Fibroblast growth factor 23, vitamin D, and health disparities among African Americans with chronic kidney disease.

Author information

1
Division of Nephrology, Department of Medicine, and Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL.

Abstract

Compared with Caucasians, African Americans have lower circulating concentrations of 25-hydroxyvitamin D (25(OH)D), the major storage form of vitamin D, leading to the widespread assumption that African Americans are at higher risk of vitamin D deficiency. However, the finding that African Americans maintain better indices of musculoskeletal health than Caucasians throughout their lifespan despite having lower circulating 25(OH)D concentrations suggests that the relationship between vitamin D deficiency and racial health disparities may not be so straightforward. The fairly recent emergence of fibroblast growth factor 23 (FGF23) may help resolve some of this uncertainty. FGF23 strongly modulates both systemic and local activation of 25(OH)D, playing a potentially important role in the degree to which lower 25(OH)D concentrations impact health outcomes, including differences in the incidence and rate of progression of chronic kidney disease by race. This review critically assesses ongoing controversies surrounding the relationship between vitamin D and racial disparities in chronic kidney disease outcomes, and how FGF23 may help to clarify the picture.

KEYWORDS:

FGF23; Vitamin D; disparities

PMID:
24119850
PMCID:
PMC3796770
DOI:
10.1016/j.semnephrol.2013.07.006
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center